GlassScriptPhysician profile
Tiffany B Turner
NPI 1629600325
$16,066.56
in general payments reported to CMS, 2019-2025
18 companies · $8,525 in 2025
The $8,525 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $921 · 2023: $3,562 · 2024: $3,059 · 2025: $8,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $3,850 · Travel and Lodging: $1,156 · Education: $59.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,079.94 |
| Consulting Fee | $3,850.00 |
| Travel and Lodging | $1,156.05 |
| Education | $59.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $9,381.09 | 2022-2025 | Yeztugo, Epclusa, Veklury |
| Viiv Healthcare Company | $2,879.91 | 2022-2025 | Dovato, Cabenuva, Apretude |
| Astrazeneca Pharmaceuticals LP | $1,150.92 | 2024-2025 | Tezspire, Fasenra |
| Abbvie INC. | $1,000.84 | 2022-2025 | |
| Lilly USA, LLC | $487.48 | 2022-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $227.64 | 2023-2025 | Pifeltro, Delstrigo, Dificid |
| Merz North America, INC. | $168.58 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $149.25 | 2023 | Austedo Xr, Austedo |
| Alkermes, INC. | $128.63 | 2022-2023 | Vivitrol |
| Janssen Biotech, INC. | $122.59 | 2023 | Prezcobix |
| Emd Serono, INC. | $108.80 | 2025 | Serostim |
| Novo Nordisk INC | $63.78 | 2022-2023 | Ozempic, Rybelsus |
| Theratechnologies INC. | $63.58 | 2022-2024 | Egrifta Sv, Egrifta, Trogarzo |
| Hologic Sales and Service, LLC | $42.41 | 2024-2025 | Aptima |
| Orexo US, INC. | $33.63 | 2023 | Zubsolv |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $23.00 | 2023 | Veozah |
| Amgen INC. | $18.26 | 2024 | Otezla, Repatha |
| Pfizer INC. | $16.17 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.